ANRO (Alto Neuroscience Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by ANRO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-29 | Andrew Craig Miller | Director | A | — | — |
| 2026-05-15 | Amit Etkin | PRESIDENT AND CEO | G | — | — |
| 2026-05-14 | Andrew Dreyfus | Director | A | — | — |
| 2026-05-14 | Husseini Manji | Director | A | — | — |
| 2026-05-14 | Ramiro Sanchez | Director | A | — | — |
| 2026-05-14 | Gwill York | Director | A | — | — |
| 2026-05-14 | Christopher Nixon Cox | Director | A | — | — |
| 2026-03-03 | Amit Etkin | PRESIDENT AND CEO | F | — | — |
| 2026-03-03 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | F | — | — |
| 2026-02-13 | Jr. Michael Conick Hanley | CHIEF OPERATING OFFICER | A | — | — |
| 2026-02-13 | Adam Savitz | CHIEF MEDICAL OFFICER | A | — | — |
| 2026-02-13 | Amit Etkin | PRESIDENT AND CEO | A | — | — |
| 2026-02-13 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | A | — | — |
| 2026-01-06 | Christopher Nixon Cox | Director | A | — | — |
| 2026-01-06 | Ramiro Sanchez | Director | A | — | — |
| 2026-01-06 | Husseini Manji | Director | A | — | — |
| 2026-01-06 | Gwill York | Director | A | — | — |
| 2025-08-14 | Ramiro Sanchez | Director | A | — | — |
| 2025-07-08 | Amit Etkin | PRESIDENT AND CEO | MIXED | — | — |
| 2025-07-08 | Jr. Michael Conick Hanley | CHIEF OPERATING OFFICER | MIXED | — | — |
| 2025-07-08 | Adam Savitz | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2025-07-08 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | MIXED | — | — |
| 2025-05-15 | Christopher Nixon Cox | Director | A | — | — |
| 2025-05-15 | Andrew Dreyfus | Director | A | — | — |
| 2025-05-15 | Gwill York | Director | A | — | — |
| 2025-05-15 | Husseini Manji | Director | A | — | — |
| 2025-02-07 | Jr. Michael Conick Hanley | CHIEF OPERATING OFFICER | A | — | — |
| 2025-02-07 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER & CBO | A | — | — |
| 2025-02-07 | Amit Etkin | PRESIDENT AND CEO | A | — | — |
| 2025-02-07 | Adam Savitz | CHIEF MEDICAL OFFICER | A | — | — |
| 2025-01-06 | Husseini Manji | Director | A | — | — |
| 2025-01-06 | Gwill York | Director | A | — | — |
| 2025-01-06 | Christopher Nixon Cox | Director | A | — | — |
| 2024-07-11 | Adam Savitz | CHIEF MEDICAL OFFICER | Buy | — | — |
| 2024-05-22 | Jr. Michael Conick Hanley | Chief Operating Officer | A | — | — |
| 2024-04-01 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER | Buy | — | — |
| 2024-03-12 | Maha Radhakrishnan | Director | A | — | — |
| 2024-03-06 | Apeiron Investment Group Ltd. | — | C | — | — |
| 2024-03-05 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER | A | — | — |
| 2024-03-05 | Adam Savitz | CHIEF MEDICAL OFFICER | A | — | — |
| 2024-03-05 | Amit Etkin | PRESIDENT AND CEO | A | — | — |
| 2024-02-08 | Chimera Investment LLC | 10%+ Owner | MIXED | — | — |
| 2024-02-07 | Nicholas Conrad Smith | CHIEF FINANCIAL OFFICER | Buy | — | — |
| 2024-02-07 | Amit Etkin | PRESIDENT AND CEO | MIXED | — | — |
| 2024-02-07 | Po Yu (Jeff) Chen | Director | C | — | — |
| 2024-02-07 | Gwill York | Director | C | — | — |
| 2024-02-07 | Christopher Nixon Cox | Director | C | — | — |
| 2024-02-07 | Adam Savitz | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2024-02-05 | Po Yu (Jeff) Chen | Director | A | — | — |
| 2024-02-05 | Christopher Nixon Cox | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,962,995 | — |
| — | — | 926,539 | — |
| — | PRESIDENT AND CEO | 833,949 | — |
| — | Director | 588,898 | — |
| — | Director | 39,259 | — |
| — | CHIEF MEDICAL OFFICER | 36,920 | — |
| — | CHIEF FINANCIAL OFFICER & CBO | 24,060 | — |
| — | Director | 23,917 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ANRO quote page; the site-wide leaderboard is on the insider transactions hub.